Xaggitin XL Prolonged-release tablets (methylphenidate)
Class 4 medicines defect notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release tablets.
Published: 21 July 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification. Macarthys Laboratories Ltd T/A Martindale Pharma has notified the MHRA of a manufacturing issue impacting several batches of Xaggitin XL prolonged-release tablets, due to the occurrence of incorrect tablet counts in the bottles. The majority of reports are for missing tablets but extra tablets have also been reported.
The quality of the tablets is not impacted by this defect and therefore the product is not being recalled.
Further information, advice and details of the affected batches can be found on the MHRA website.